Comparative Pharmacology
Head-to-head clinical analysis: HYDROMORPHONE HYDROCHLORIDE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROMORPHONE HYDROCHLORIDE versus WESTADONE.
HYDROMORPHONE HYDROCHLORIDE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydromorphone is a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the CNS, activating G-protein coupled receptors that inhibit adenylate cyclase, decrease cAMP production, and modulate ion channels, leading to reduced neurotransmitter release (e.g., substance P, glutamate) and hyperpolarization of neurons. This results in analgesia, sedation, and euphoria.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Initial: 2-4 mg orally every 3-4 hours; 1-2 mg intravenously/subcutaneously/intramuscularly every 2-4 hours. For opioid-naive patients, lower starting doses (e.g., 1-2 mg oral, 0.2-0.5 mg parenteral) are recommended.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life: 2.0–3.0 hours in healthy adults; prolonged in renal impairment (up to 40 hours) and hepatic impairment; clinical context: supports dosing interval of 4–6 hours in normal renal function.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Primarily renal (approximately 90% as hydromorphone-3-glucuronide and other conjugates; <7% as unchanged hydromorphone), with a small amount biliary/fecal.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist